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Abstract
Questions have been raised on the clinical value of the metabolic syndrome (MS). The negative 
opinion regarding MS is anchored basically on a separate analysis of 4 conditions: obesity, 
dyslipidemia, hypertension and glucose intolerance. The common denominator of these 4 sets 
of arguments is that they represent an utterly simplistic view of MS as a solely predictive tool 
of morbidity or mortality. We believe that it is inequitable to compare it with statistically con-
structed predictive tools, including stronger prognostic variables even unrelated to one another 
from the biological point of view. Several recent large meta-analyses — one of them including 
nearly one million patients — systematically showed that people with MS are at increased risk 
of cardiovascular (CV) events. MS was associated with a 2-fold increase in CV outcomes and 
a 1.5-fold increase in all-cause mortality rates. A very important finding was that CV risk 
still remained high in patients with MS but without diabetes. The presence of MS possesses  
a definitely predictive value, but above all it is a widely accepted concept regarding a biological 
condition based on complex and interrelated pathophysiological mechanisms emanating from 
excess central adiposity and insulin resistance. The risk factors are multiplicative, meaning 
that the risk of a CV disease from risk factors rises geometrically, not linearly, as the number 
of risk factors increases. Therefore, currently available evidences strongly support the concept 
of the MS as a critical clustering of CV risk factors and diabetes, representing a true and solid 
evolving clinical entity. (Cardiol J 2014; 21, 1: 1–5)
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Introduction
During the last few years, an enormous 
amount of articles have been published regarding 
a relatively new diagnostic category: the metabolic 
syndrome (MS). These articles have proliferated 
in medical literature in the fields of internal me-
dicine, cardiology, endocrinology, metabolism, 
hypertension and related disciplines. Initially, in 
1988 Reaven [1] proposed a conceptual framework 
which linked several apparently unrelated biologi-
cal events into a single pathophysiological assem-
ble. His hypothesis argued that insulin resistance 
triggered a common mechanism underlying the 
associated abnormalities of blood pressure, high 
density lipoprotein cholesterol (HDL-C), trigly-
cerides (TG) and glucose tolerance. This concept 
subsequently evolved to encompass a number of 
multiple definitions [2] established by the World 
Health Organization (WHO) [3], the National 
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Cholesterol Education Program Adult Treatment 
Panel III (ATP III) [4], the European Group for 
the Study of Insulin Resistance [5] and the Inter-
national Diabetes Federation (IDF) [6]. Central 
obesity has been added to the above mentioned risk 
factors, which were ranked in different pathogenic 
priorities and with dissimilar cut-off points for the 
individual risk factors [7]. More recently, the IDF 
and the modified ATP III definitions have become 
more concordant, with the remaining difference 
pertaining to waist measurement [8].
However, questions have been raised concer-
ning the clinical value of the MS [9]. Perhaps the 
most direct assault on the theory has been issued 
in a joint report [10] from the American Diabetes 
Association (ADA) and the European Association 
for the Study of Diabetes (EASD), which questions 
the very existence of MS. In sharp contrast, a joint 
position paper from the American Heart Asso-
ciation and the National Heart, Lung, and Blood 
Institute, firmly defends the concept [11].
In the present review we deal with the pros 
and cons of this issue. We will firstly briefly de-
scribe the main arguments against the survival of 
MS as an independent clinical entity. Then, we are 
going to offer the current evidence to the contrary, 
in an attempt to cut the Gordian knot around the 
MS entanglement.
Cons
The negative opinion regarding the syndro-
me is anchored on the analysis of 4 conditions: 
obesity, dyslipidemia, hypertension and glucose 
intolerance.
First, regarding obesity it may be argued that 
excess adiposity is not a consequence of insulin 
resistance, but a change that increases the like-
lihood that an individual will be insulin resistant. 
In addition, not all obese individuals are insulin 
resistant [12] and, as a corollary, the risk factors for 
cardiovascular disease (CVD) should be confined to 
the subset of obese individuals who are also insulin 
resistant [13]. Obesity, per se, in the absence of 
the metabolic characteristics of insulin resistance, 
should not increase the incidence of either CVD or 
type 2 diabetes mellitus (T2DM) [14].
Second, there is a highly significant relation-
ship between insulin resistance, compensatory 
hyperinsulinemia, and hypertriglyceridemia [15], 
which is not limited to an increase in plasma TG 
concentrations. Thus, although various definitions 
of MS have selected the combination of a high 
plasma TG and a low HDL-C concentration as 
diagnostic criteria, these changes are also asso-
ciated with a decrease in low-density lipoprotein 
(LDL) and the postprandial accumulation of TG- 
-rich remnant lipoproteins [16]. Both high TG and 
low HDL-C have been shown to increase risk of 
CVD [17] and may develop for reasons other than 
insulin resistance/hyperinsulinemia.
Third, essential hypertension is intimately lin-
ked to insulin resistance/hyperinsulinemia. Firstly, 
as a group, patients with essential hypertension are 
insulin resistant and hyperinsulinemic [18]. Secon-
dly, normotensive first-degree relatives of patients 
with essential hypertension are relatively insulin 
resistant and hyperinsulinemic as compared to 
a matched control group without a family history 
of hypertension [19]. Thirdly, hyperinsulinemia, as 
a surrogate estimate of insulin resistance, has been 
shown in population-based studies to predict the 
eventual development of essential hypertension 
[20]. These data provide substantial support for 
the theory that insulin resistance/hyperinsulinemia 
plays a role in the pathogenesis of essential hyper-
tension [9]. On the other hand, probably no more 
than 50% of patients with essential hypertension 
are insulin resistant [21]. However, it is only this 
subset of patients that display the components of 
the various definitions of MS that render them at 
greatest risk for CVD [9].
Fourth, it is well established that prevalence 
of some degree of abnormal glucose tolerance 
and/or T2DM is the abnormality most closely 
related to insulin resistance. More than 70 years 
ago Himsworth and Kerr presented evidence that 
“a state of diabetes might result from inefficient 
action of insulin as well as from a lack of insulin” 
[22]. Nowadays it is quite clear that resistance 
to insulin-mediated glucose disposal is present 
in great majority of individuals with T2DM [23], 
and that insulin resistance (or hyperinsulinemia 
as a surrogate estimate of insulin resistance) is 
a powerful and independent predictor of the deve-
lopment of T2DM [24].
Therefore, taking into consideration the 4 cla-
ims, the criteria for the syndrome will encompass 
individuals with overt disease (like CVD, T2DM, 
hypertension), as well as with far milder forms of 
the same conditions. The definition will capture 
a spectrum of severities, and it is highly likely that 
a person who satisfies the diagnostic criteria with 
risk factor levels just over the cut point will have 
a much lower CVD risk than another individual 
with the same combination but higher risk factor 
levels [10].
www.cardiologyjournal.org 3
Enrique Z. Fisman, Alexander Tenenbaum, The metabolic syndrome entanglement: Cutting the Gordian knot
Pros
The common denominator of the above men-
tioned 4 sets of arguments is that they represent an 
utterly simplistic view of MS as a solely predictive 
tool of morbidity or mortality [25]. Of course, the 
presence of MS possesses a definite predictive 
value, but first of all it is a widely accepted con-
cept regarding a biological condition based on the 
complex and interrelated pathophysiological me-
chanisms emanating from excess central adiposity 
and insulin resistance. Therefore, it is inequitable 
to compare it with statistically constructed predic-
tive tools, including stronger prognostic variables 
even unrelated to one another from the biological 
point of view. For example, in the criteria for MS 
(in contrast to Framingham score) age and LDL 
cholesterol (LDL-C) levels are not included, as 
well as a variety of strong predictors used in other 
risk stratification scores: previous myocardial 
infarction, heart failure, smoking, family history, 
etc. However, MS identifies additional important 
residual vascular risk mainly associated with insu-
lin resistance and atherogenic dyslipidemia (low 
HDL-C, high TG, small dense LDL-C). Therefore, 
MS could be a useful additional tool in estimation of 
global cardiovascular (CV) risk beyond age, gender, 
high LDL-C or other standard risk factors.
Additionally, one of the important questions 
still remaining open is its predictive value: does 
MS forecast CV events, diabetes onset or disease 
progression any better than the sum of its compo-
nents? For the time being, the strongest available 
evidence points toward a positive answer [25]. 
Three consecutive large meta-analyses syste-
matically showed that people with MS are at 
increased risk of CV events [26–28]. The most 
recent and largest of them [28] included nearly 
1 million patients (total n = 951,083). There, the 
investigators concluded that MS is associated with 
a 2-fold increase in CV outcomes and a 1.5-fold 
increase in all-cause mortality rates. That meta-
-analysis showed that the point estimates for CV 
risk were consistently higher in women than in 
men. In addition, a very important finding of this 
study demonstrated that CV risk was still high in 
patients with MS but without diabetes. Moreover, 
it was demonstrated that the syndrome predicts CV 
events or/and diabetes independently from other 
conventional risk factors [29, 30]. Our group has 
shown that MS is a strong independent predictor 
of mortality and morbidity in patients with acute 
coronary syndrome [30]. It should be specifically 
pointed out that our patients with hyperglycemia 
and MS had higher mortality rates compared with 
patients with the same hyperglycemia but without 
MS (for example 30-day mortality rates respecti-
vely 8.3% vs. 2.5%, p < 0.05).
Analyzing the progression of carotid athero-
sclerosis, it should be stressed that subjects with 
MS have higher levels of intima–media thickness 
(IMT) and total plaque area at follow up than those 
without MS. MS predicts progression of IMT in in-
dividuals below 50 years of age, but not in older age 
groups, suggesting thus that MS may be involved in 
the initial steps of the atherosclerotic process [31].
Another argument in favor of the biological 
soundness of MS is based on experimental rese-
arch. For instance, it should be noted that GLUT4 
expression, accompanied by whole-body insulin 
resistance and increased plasma concentration of 
inflammatory biomarkers was found in an animal 
model of MS [32], similarly, it has been observed 
in humans.
Even critics of the MS concept should agree 
that obesity, dysglycemia, dyslipidemia and hyper-
tension coexist more frequently than predicted by 
mere chance. These common chronic conditions 
(and components of MS) have partially overlap-
ping mechanisms of pathogenic actions mediated 
through common metabolic pathways. Therefore, 
their total combined effect could be less than the 
sum of the individual effects [25].
Emerging varied areas of current MS research 
interests include heterogeneous topics like adipo-
nectin and biomarkers preserving endothelial he-
alth [33, 34], angiotensinogen, resistin, and leptin 
secretion [33], nonalcoholic fatty liver disease and 
liver steatosis [35], hyperuricemia [36], genetic 
predisposition [37], the role of adypocytokines and 
neurohumoral dysregulation [38]; sleep disorders 
and ethnicity [39], the possible ways for treatment 
optimization in patients with CVD [40]. Additional 
related matters are currently investigated, like heart 
rate (HR) turbulence; it has been shown that this 
turbulence — a well-established predictor of cardiac 
autonomic dysfunction — is significantly impaired 
in MS patients without T2DM in adults [41]. Re-
garding childhood and adolescence, HR variability 
is disturbed in children [42], and several equations 
have been developed in order to early identify and 
adequately treat MS in young populations, taking 
into consideration racial, ethnic and gender diffe-
rences [43]. A multimarker approach to MS could 
further improve CV risk stratification [44].
The concept that the MS is a consequence of 
obesity and insulin resistance, provides a useful 
“life-style changes” approach for prevention and 
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treatment: caloric restriction, weight-loss and 
increased physical activity. The next step could 
theoretically be pharmacological interventions 
such as metformin, acarbose, fibrates, weight-loss 
drugs (like orlistat) and perhaps glucagon-like 
peptide-1 agonists [45] or eventual new drugs to 
simultaneously treat several risk factors. A third 
step is represented by the surgical approach. 
A recent study authored by Rizzello et al. [46] and 
performed according to the updated guidelines 
for meta-analyses of non-randomized studies [47] 
depicts several promising surgical approaches for 
MS, including adjustable silicone gastric banding, 
Roux-en-Y gastric bypass, biliopancreatic diversion 
and bariatric surgery.
Conclusions
Currently available evidences strongly support 
the concept of MS as very far of being factitious. 
Quite the opposite, it is a critical clustering of CV 
risk factors and diabetes, representing a true and 
solid evolving clinical entity. These risk factors are 
multiplicative, meaning that the risk for CVD from 
risk factors rises geometrically, not linearly, as the 
number of risk factors increases. Therefore, the 
total risk that MS represents is much more than 
a mere summation of the isolated factors [48, 49]. 
MS is a multifactorial syndrome, standing firstly on 
2 tightly intertwined conditions: obesity and insu-
lin resistance; obesity causes insulin resistance, 
and on the other hand, insulin resistance modifies 
adipose tissue responses to insulin and thereby 
recapitulates the obese state. This situation is 
exacerbated by the concomitant factors [11, 48]. 
MS prevention, recognition, treatment, and better 
understanding of its underlying mechanisms should 
become an important approach for the reduction 
of CVD burden in the general population. Future 
problem-oriented research is needed to improve 
and unify its diagnostic criteria, its genetic and 
environmental basis and the optimal medical ma-
nagement.
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